Boehringer Ingelheim International Gmbh

Centrexion Therapeutics Corporation

Merck Sharp + Dohme Corp.

Arena Pharmaceuticals, Inc.

Instituto Di Ricerche Di Biologia Molecolare P. Angeletti

Msd Italia S.r.l.

Antios Therapeutics, Inc.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Merck Canada Inc.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

Marco Ferrara

Riccardo Giovannini

Niklas Heine

Iain Lingard

Rocco Mazzaferro

Uta Friederike Lessel

Doris Riether

Scott Hobson

Barbara Bertani

Klaus Rudolf

Janet Rachel Nicholson

Giacomo Fossati

Christoph Hoenke

Sara Frattini

Henri Doods

Vincenzo Summa

Raimund Kuelzer

Stefan Scheuerer

Steven Harper

Nigel J Liverton

John A McCauley

Kai Gerlach

Yifeng Xiong

Michael T Rudd

Graeme Semple

Holger Rosenbrock

Samuel Chackalamannil

Yongxin Han

Srikanth Venkatraman

Gerhard Schaenzle

Maria Emilia Di Francesco

Michael Rowley

Christian Eickmeier

Matteo Iannacone

John W Butcher

Uwe Koch

Francisco Velazquez

M Katharine Holloway

Unmesh G Shah

Joseph J Romano

Viktor Vintonyak

Cristina Gardelli

Benoit Bachand

Kevin F Gilbert

Anton Pekcec

Yunhai Cui

Stefan Just

Ursula Mueller-Vieira

Helmi Zaghdane

Benedetta Crescenzi

Virender Singh Aulakh

Adolfo Prandi

Patrick Beaulieu

Monica Donghi

Daniela Berta

Pietro Randazzo

Leda Ivanova Bencheva

Marilenia De Matteo

Julian Wippich

Marco Pompei

Radoslaw Lipinski

Raffaele De Francesco

Lorena Donnici

Luca Guidotti

Romano Di Fabio

Davide Gornati

Alessandro Grillo

Luca Ferrante

Frank Runge

Kirsten Gutsche

Christiane Grisé-Bard

Marie-Christine Brochu

Sylvie Charron

Marcello Di Filippo

John Mccauley

Marie-Christine Brouchu

Unmesh Shah

Charles J Mcintyre

Alessia Petrocchi

The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of formula (I) wherein R, R, R, R, Rand A are as defined herein. The compounds of formula (1) are inhibitors of phosphodiesterase 2 and useful in treating central nervous system diseases and other diseases. The invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide

The invention relates to 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) for use as a medicament, pharmaceutical compositions comprising at least a compound of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament

The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Substituted 3-phenoxyazetidin-1-yl-pyrazines

The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.

Tricyclic inhibitors of Hepatitis B virus

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)-propanyl]- and N-[(Pyrazinylamino)&#xac;propanyl]arylcarboxamide such as compound  The present invention also relates to derivatives of such compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R, R, R, R, R, Rand Rhave meanings given in the description. 

N-[(pyridyloxy)propanyl]benzamides

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Arand Arhave meanings given in the description. 

N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides

3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.

Somatostatin receptor subtype 4 (SSTR4) agonists

This invention relates to compounds of formula I a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R, Rand Rhave meanings given in the description.

N-[(pyrazinyloxy)propanyl]benzamides as antagonists of orexin subtype 1 receptor activity

The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.

Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R, R, R, R, Rhave meanings given in the description. 

N-[(pyrimidinyloxy)propanyl]benzamides

Growing community of inventors

San Donato Milanese, Italy

Marco Ferrara